Australia’s Neurizon Therapeutics, a biotech advancing innovative treatments for neurodegenerative diseases, has reported positive top-line results from the Open-Label Extension (OLE) study of its ...

The UK’s National Institute for Health and Care Excellence (NICE) has today (August 21) recommended the use of Japanese pharma major Astellas’ enfortumab vedotin with MSD’s Keytruda (pembrolizumab) ...